129 related articles for article (PubMed ID: 24866725)
1. Nanostructured lipid carriers as a potential vehicle for Carvedilol delivery: Application of factorial design approach.
Patil GB; Patil ND; Deshmukh PK; Patil PO; Bari SB
Artif Cells Nanomed Biotechnol; 2016; 44(1):12-9. PubMed ID: 24866725
[TBL] [Abstract][Full Text] [Related]
2. Fabrication of novel GMO/Eudragit E100 nanostructures for enhancing oral bioavailability of carvedilol.
Patil SS; Roy K; Choudhary B; Mahadik KR
Drug Dev Ind Pharm; 2016 Aug; 42(8):1300-7. PubMed ID: 26651381
[TBL] [Abstract][Full Text] [Related]
3. Carvedilol nano lipid carriers: formulation, characterization and in-vivo evaluation.
Mishra A; Imam SS; Aqil M; Ahad A; Sultana Y; Ameeduzzafar ; Ali A
Drug Deliv; 2016 May; 23(4):1486-94. PubMed ID: 26978072
[TBL] [Abstract][Full Text] [Related]
4. Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation.
Paudel A; Ameeduzzafar ; Imam SS; Fazil M; Khan S; Hafeez A; Ahmad FJ; Ali A
Curr Drug Deliv; 2017; 14(7):1005-1015. PubMed ID: 28034361
[TBL] [Abstract][Full Text] [Related]
5. Chlorogenic acid stabilized nanostructured lipid carriers (NLC) of atorvastatin: formulation, design and in vivo evaluation.
Khan S; Baboota S; Ali J; Narang RS; Narang JK
Drug Dev Ind Pharm; 2016; 42(2):209-20. PubMed ID: 26016780
[TBL] [Abstract][Full Text] [Related]
6. Development, Optimization, and Evaluation of Carvedilol-Loaded Solid Lipid Nanoparticles for Intranasal Drug Delivery.
Aboud HM; El Komy MH; Ali AA; El Menshawe SF; Abd Elbary A
AAPS PharmSciTech; 2016 Dec; 17(6):1353-1365. PubMed ID: 26743643
[TBL] [Abstract][Full Text] [Related]
7. Design and characterization of Amoitone B-loaded nanostructured lipid carriers for controlled drug release.
Luan J; Zhang D; Hao L; Li C; Qi L; Guo H; Liu X; Zhang Q
Drug Deliv; 2013 Nov; 20(8):324-30. PubMed ID: 24032657
[TBL] [Abstract][Full Text] [Related]
8. G5-PEG PAMAM dendrimer incorporating nanostructured lipid carriers enhance oral bioavailability and plasma lipid-lowering effect of probucol.
Qi R; Li YZ; Chen C; Cao YN; Yu MM; Xu L; He B; Jie X; Shen WW; Wang YN; van Dongen MA; Liu GQ; Banaszak Holl MM; Zhang Q; Ke X
J Control Release; 2015 Jul; 210():160-8. PubMed ID: 26003044
[TBL] [Abstract][Full Text] [Related]
9. Preparation, characterization and biocompatibility studies of thermoresponsive eyedrops based on the combination of nanostructured lipid carriers (NLC) and the polymer Pluronic F-127 for controlled delivery of ibuprofen.
Almeida H; Lobão P; Frigerio C; Fonseca J; Silva R; Sousa Lobo JM; Amaral MH
Pharm Dev Technol; 2017 May; 22(3):336-349. PubMed ID: 28240141
[TBL] [Abstract][Full Text] [Related]
10. Development of optimized self-nano-emulsifying drug delivery systems (SNEDDS) of carvedilol with enhanced bioavailability potential.
Singh B; Khurana L; Bandyopadhyay S; Kapil R; Katare OO
Drug Deliv; 2011 Nov; 18(8):599-612. PubMed ID: 22008038
[TBL] [Abstract][Full Text] [Related]
11. Box-Behnken study design for optimization of bicalutamide-loaded nanostructured lipid carrier: stability assessment.
Kudarha R; Dhas NL; Pandey A; Belgamwar VS; Ige PP
Pharm Dev Technol; 2015; 20(5):608-18. PubMed ID: 24785784
[TBL] [Abstract][Full Text] [Related]
12. Implications of formulation design on lipid-based nanostructured carrier system for drug delivery to brain.
Salunkhe SS; Bhatia NM; Bhatia MS
Drug Deliv; 2016 May; 23(4):1306-16. PubMed ID: 25080227
[TBL] [Abstract][Full Text] [Related]
13. Preparation of poloxamer-based nanofibers for enhanced dissolution of carvedilol.
Kajdič S; Vrečer F; Kocbek P
Eur J Pharm Sci; 2018 May; 117():331-340. PubMed ID: 29514051
[TBL] [Abstract][Full Text] [Related]
14. The effect of oil type on the aggregation stability of nanostructured lipid carriers.
Yang Y; Corona A; Schubert B; Reeder R; Henson MA
J Colloid Interface Sci; 2014 Mar; 418():261-72. PubMed ID: 24461844
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus-loaded nanostructured lipid carriers for oral delivery-in vivo bioavailability enhancement.
Khan S; Shaharyar M; Fazil M; Hassan MQ; Baboota S; Ali J
Eur J Pharm Biopharm; 2016 Dec; 109():149-157. PubMed ID: 27793753
[TBL] [Abstract][Full Text] [Related]
16. Nanostructured lipid carriers and their current application in targeted drug delivery.
Jaiswal P; Gidwani B; Vyas A
Artif Cells Nanomed Biotechnol; 2016; 44(1):27-40. PubMed ID: 24813223
[TBL] [Abstract][Full Text] [Related]
17. QbD-driven development and evaluation of nanostructured lipid carriers (NLCs) of Olmesartan medoxomil employing multivariate statistical techniques.
Beg S; Saini S; Bandopadhyay S; Katare OP; Singh B
Drug Dev Ind Pharm; 2018 Mar; 44(3):407-420. PubMed ID: 29048242
[TBL] [Abstract][Full Text] [Related]
18. Core-matched encapsulation of an oleate prodrug into nanostructured lipid carriers with high drug loading capability to facilitate the oral delivery of docetaxel.
Sun B; Luo C; Li L; Wang M; Du Y; Di D; Zhang D; Ren G; Pan X; Fu Q; Sun J; He Z
Colloids Surf B Biointerfaces; 2016 Jul; 143():47-55. PubMed ID: 27011346
[TBL] [Abstract][Full Text] [Related]
19. Nanostructured lipid carriers used for oral delivery of oridonin: an effect of ligand modification on absorption.
Zhou X; Zhang X; Ye Y; Zhang T; Wang H; Ma Z; Wu B
Int J Pharm; 2015 Feb; 479(2):391-8. PubMed ID: 25556104
[TBL] [Abstract][Full Text] [Related]
20. Process, optimization, and characterization of budesonide-loaded nanostructured lipid carriers for the treatment of inflammatory bowel disease.
Sinhmar GK; Shah NN; Chokshi NV; Khatri HN; Patel MM
Drug Dev Ind Pharm; 2018 Jul; 44(7):1078-1089. PubMed ID: 29376433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
